Not Yet Recruiting
NA
INTERVENTIONAL
NCT06301256
Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to determine the clinical efficacy and safety of tirzepatide in subjects with moderate to severe hidradenitis suppurativa. The study will be conducted over 24 weeks on active therapy followed by a eight-week observational follow-up visit. The total length of the study will be 32 weeks .
Interventions
Name:
TIRZEPATIDE
Type:
DRUG
Description:
Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.
Primary Outcomes
Measure:
Hidradenitis Suppurativa Clinical Response (HiSCR) 50%
TimeFrame:
24 Weeks
Description:
The proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at week 24, defined as a 50% reduction in the total number of inflammatory nodule count, as long as the number of fistulae and abscesses don't increase.
Trial Information
NCT ID
NCT06301256
Status
Not Yet Recruiting
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
Florida Academic Centers Research and Education, LLC
Last Updated
December 15, 2025